Fifteen years ago or so was the first time I wrote about the endlessly fascinating multi-purpose inexpensive Low Dose Naltrexone (LDN). Among the majority of conventional physicians, the “needle” has moved slightly from “never heard of it” to “I’ve heard of it but don’t prescribe it.” I guess you could call it a ‘guarded improvement.’ […]

Ten years ago last April marks the anniversary of the first time I wrote about low-dose naltrexone (LDN). I described it as an orphan drug, meaning that its patent had long ago expired, that it was generic, and that it was not owned by any one company. For these reasons and because they’d never recoup […]

Ten years ago April marks the anniversary of the first time I wrote about low-dose naltrexone (LDN). I described it as an orphan drug, meaning that its patent had long ago expired, that it was generic, and that it was not owned by any one company. For these reasons and because they’d never recoup their […]